| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The knockout mouse project.
|
Nat Genet
|
2004
|
7.80
|
|
2
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Cancer Discov
|
2011
|
7.57
|
|
3
|
Sorafenib-induced premalignant and malignant skin lesions.
|
Int J Dermatol
|
2011
|
2.52
|
|
4
|
DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
|
J Clin Oncol
|
2011
|
2.34
|
|
5
|
Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
|
Nat Rev Clin Oncol
|
2010
|
2.26
|
|
6
|
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
|
Clin Cancer Res
|
2010
|
2.14
|
|
7
|
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
1.79
|
|
8
|
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.74
|
|
9
|
House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1.
|
J Immunol
|
2002
|
1.72
|
|
10
|
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.71
|
|
11
|
Novel therapeutic targets in non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
1.54
|
|
12
|
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy.
|
J Thorac Oncol
|
2007
|
1.48
|
|
13
|
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.
|
J Thorac Oncol
|
2008
|
1.29
|
|
14
|
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
|
J Thorac Oncol
|
2012
|
1.28
|
|
15
|
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
Sci Transl Med
|
2012
|
1.27
|
|
16
|
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
|
J Natl Cancer Inst
|
2011
|
1.27
|
|
17
|
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
|
Clin Cancer Res
|
2013
|
1.14
|
|
18
|
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.
|
PLoS One
|
2010
|
1.12
|
|
19
|
Translating clinical trials into meaningful outcomes.
|
Clin Cancer Res
|
2010
|
1.11
|
|
20
|
Tissue platinum concentration and tumor response in non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
1.11
|
|
21
|
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
|
J Thorac Oncol
|
2012
|
1.06
|
|
22
|
CXCR4 chemokine receptor antagonists: perspectives in SCLC.
|
Expert Opin Investig Drugs
|
2009
|
1.04
|
|
23
|
Genetic variants in cell cycle control pathway confer susceptibility to lung cancer.
|
Clin Cancer Res
|
2007
|
1.04
|
|
24
|
Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
|
Expert Rev Anticancer Ther
|
2011
|
1.03
|
|
25
|
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
|
Lung Cancer
|
2010
|
1.02
|
|
26
|
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.
|
PLoS One
|
2012
|
1.00
|
|
27
|
Imaging of the patient with non-small cell lung cancer.
|
Radiology
|
2005
|
0.99
|
|
28
|
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
|
J Clin Oncol
|
2009
|
0.99
|
|
29
|
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
|
Clin Cancer Res
|
2012
|
0.98
|
|
30
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Clin Cancer Res
|
2013
|
0.95
|
|
31
|
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
|
J Thorac Oncol
|
2011
|
0.94
|
|
32
|
Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.
|
Cancer
|
2009
|
0.94
|
|
33
|
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.
|
Carcinogenesis
|
2011
|
0.91
|
|
34
|
Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.
|
J Clin Oncol
|
2007
|
0.90
|
|
35
|
Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.
|
Carcinogenesis
|
2012
|
0.90
|
|
36
|
Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.89
|
|
37
|
Randomized phase II trials: misleading and unreliable.
|
J Clin Oncol
|
2010
|
0.88
|
|
38
|
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
|
J Thorac Oncol
|
2013
|
0.87
|
|
39
|
ATM sequence variants associate with susceptibility to non-small cell lung cancer.
|
Int J Cancer
|
2007
|
0.86
|
|
40
|
Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model.
|
J Pharm Pharm Sci
|
2005
|
0.85
|
|
41
|
An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield.
|
Int J Mol Med
|
2002
|
0.84
|
|
42
|
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
|
J Thorac Oncol
|
2011
|
0.82
|
|
43
|
Compliance in early-phase cancer clinical trials research.
|
Oncologist
|
2013
|
0.81
|
|
44
|
Determining the critical micelle concentration of a novel lipid-lowering agent, disodium ascorbyl phytostanyl phosphate (FM-VP4), using a fluorescence depolarization procedure.
|
Drug Dev Ind Pharm
|
2004
|
0.80
|
|
45
|
Systemic therapy for lung cancer brain metastases: a rationale for clinical trials.
|
Oncology (Williston Park)
|
2008
|
0.80
|
|
46
|
Nuclear war between Israel and Iran: lethality beyond the pale.
|
Confl Health
|
2013
|
0.79
|
|
47
|
Recovery of Mycobacterium avium subspecies paratuberculosis from the natural host for the extraction and analysis in vivo-derived RNA.
|
J Microbiol Methods
|
2004
|
0.79
|
|
48
|
Redefining cancer: a new paradigm for better and faster treatment innovation.
|
J Popul Ther Clin Pharmacol
|
2014
|
0.79
|
|
49
|
Before we throw out progression-free survival as a valid end point...
|
J Clin Oncol
|
2012
|
0.78
|
|
50
|
Chlorine dioxide oxidation of guanosine 5'-monophosphate.
|
Chem Res Toxicol
|
2006
|
0.77
|
|
51
|
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
|
J Thorac Oncol
|
2011
|
0.77
|
|
52
|
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.76
|
|
53
|
Cancer research in the United States: dying by a thousand paper cuts.
|
Cancer
|
2013
|
0.76
|
|
54
|
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
|
Cancer
|
2010
|
0.75
|
|
55
|
Gefitinib maintenance in stage III non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
0.75
|
|
56
|
Sensitization of ultra-long-range excited-state electron transfer by energy transfer in a polymerized film.
|
Proc Natl Acad Sci U S A
|
2012
|
0.75
|
|
57
|
Chemotherapy dose intensity and survival in non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.75
|
|
58
|
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
|
J Natl Cancer Inst
|
2008
|
0.75
|
|
59
|
Varying substituents and solvents to maximize the luminescence from [Ru(trpy)(bpy)CN]+ derivatives.
|
Inorg Chem
|
2013
|
0.75
|
|
60
|
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
|
Cancer Biomark
|
2012
|
0.75
|
|
61
|
Rigid medium effects on photophysical properties of MLCT excited states of polypyridyl Os(II) complexes in polymerized poly(ethylene glycol)dimethacrylate monoliths.
|
J Phys Chem A
|
2014
|
0.75
|
|
62
|
Excited-state dynamics in rigid media: evidence for long-range energy transfer.
|
J Phys Chem B
|
2013
|
0.75
|
|
63
|
Strong triplet excited-state absorption in a phenanthrolinyl iridium(III) complex with benzothiazolylfluorenyl-substituted ligands.
|
Opt Lett
|
2015
|
0.75
|
|
64
|
Organic component vapor pressures and hygroscopicities of aqueous aerosol measured by optical tweezers.
|
J Phys Chem A
|
2015
|
0.75
|
|
65
|
An amide-linked chromophore-catalyst assembly for water oxidation.
|
Inorg Chem
|
2012
|
0.75
|